An appalling 40 percent of Americans get cancer, and it’s no surprise that most people know at least one person that has cancer. About 14.5 million people living in the United States had cancer in 2014, according to the National Cancer Institute. That statistic is expected to rise to over 19 million by the end of 2024.
Eric Lefkofsky, co-founder of Groupon and Tempus, is at the helm of the data-enabled medicine. His wife was one of the statistics that had gotten breast cancer, and he got to know firsthand what it felt like to be faced with the disease. Although it may seem like the healthcare industry has a handle on the technology of our day, it couldn’t be further than the truth.
There is plenty of information on patients and their treatments, but there is no productive or efficient protocol when it comes to handling all that information.
Fortunately, Tempus is a company that is working hard to deliver better results as far as cancer care is concerned. The company created a platform that is more efficient at analyzing molecular and clinical data. They are working hard to offer not only accessible but affordable data as well.
Tempus has had its fair share of challenges, but they have developed software to help them to handle difficulties such as language processing and character recognition. Tempus is also helping to lower the cost of sequencing.
Lefkofsky is confident that companies such as tempus will help doctors to more accurately pair patients with the proper treatments and they will be able to find the proper medications as well.
Eric Lefkofsky graduated from the University of Michigan and obtained his Juris Doctor at the University of Michigan Law School, is CEO of Tempus, and he is also a partner of Lightbank as well as co-founder of Groupon and Uptake Technologies.
He established the Lefkofsky foundation in 2006, and he is a Trustee of Lurie Children’s Hospital of Chicago, and Art Institute of Chicago. He is also a professor at the University of Chicago and he has even written and published Accelerated Disruption.